ClinicalTrials.gg
Active, not recruitingNCT05465122C2LOEUpdated May 28, 2026

CREST-2 Long-term Observational Extension Study

An observational study in Stenoses, Carotid, sponsored by Mayo Clinic. Active, not recruiting at 64 sites in 3 countries. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Mayo Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,480
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 84 studies in Carotid Stenosis with a site in United States — 6 open to participants now, 13 under way, none of them phase 3. Carotid Stenosis · United States.

Planned enrollment
2nd of 31
2,480 · median 114
Started
2022
with 3 others
Observational
31 of 84
2 open now
Primary completion
2027-08
later than 7 of 12 live
Registered
78th of 84
by date
Lead sponsor
5 of 84
Mayo Clinic

Among the 84 studies in Carotid Stenosis with a site in United States, this one is the 2nd largest by planned enrollment of the 31 observational ones that give a count, is one of 4 that started in 2022, is one of 31 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 78th registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

6 of the 84 studies in Carotid Stenosis with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Carotid Stenosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial (C2LOE - ClinicalTrials.gov Identifier: NCT02089217) study is to study is to assess post-procedural efficacy of carotid endarterectomy and carotid stenting.

Read the detailed description

Atherosclerotic plaque in the carotid arteries is responsible for 10 to 15% of all ischemic strokes. The ongoing NINDS-funded CREST-2 multicenter randomized clinical trial is testing whether in the short term (up to 4 years after study entry) procedural revascularization improves stroke prevention above and beyond what can be achieved with intensive medical management of vascular risk factors, especially hypertension and hyperlipidemia. Our proposal is for an observational extension of the CREST-2 clinical trial to test whether revascularization improves stroke prevention in the clinically relevant long term (up to 8 to 10 years). The current application proposes to use a site-less, centralized telephone approach to extend the follow-up of CREST-2 trial participants for assessing the primary study outcome (stroke) for up to 10 years. The average follow-up will increase from between 2-3 years (clinic-based randomized trial) to 7-8 years (observational extension). Each patient will be contacted by telephone at 6-month intervals, and queried regarding all hospitalizations since the last contact. Suspected stroke events will be adjudicated by an expert clinical events committee based on medical record review.

03

Conditions studied

  • Stenoses, Carotid

Browse trials for

04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with asymptomatic carotid stenosis previously randomized in the CREST-2 trial.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Currently active or graduated participants in the CREST-2 randomized trial
  • Able to provide written by self
  • Fluent in English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Unable to provide written
  • Inability to follow study procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,480 participants (estimated)
Patient registry
No

Groups and cohorts

  • Carotid Stenting Group (CAS)

    Subjects assigned to the intensive medical management with carotid stenting group in the CREST-2 study (NCT02089217)

    Procedure: FDA-approved carotid stents · Other: Intensive Medical Management

  • Carotid Endarterectomy Group (CEA)

    Subjects assigned to the intensive medical management with carotid endarterectomy group in the CREST-2 study (NCT02089217)

    Procedure: Carotid Endarterectomy · Other: Intensive Medical Management

  • Intensive Medical Management Group - no CAS

    Subjects assigned to the intensive medical management alone with no carotid stenting (CAS) group in the CREST-2 study (NCT02089217)

    Other: Intensive Medical Management

  • Intensive Medical Management Group - no CEA

    Subjects assigned to the intensive medical management alone with no carotid endarterectomy (CEA) group in the CREST-2 study (NCT02089217)

    Other: Intensive Medical Management

Interventions

  • ProcedureCarotid Endarterectomy

    This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.

  • ProcedureFDA-approved carotid stents

    This is the standard proven therapy for carotid stenosis that involves an arteriotomy followed by removal of plaque and reconstruction of the vessel.

  • OtherIntensive Medical Management

    INTERVENT risk factor management program to help manage patient's risk factors. The INTERVENT program will provide individualized risk factor counseling sessions (via telephone or internet) at regular interval by healthcare workers who are specially trained to help patients follow the medical management plan.

06

What researchers measure

Primary outcomes

  1. Stroke

    Number of participants to experience a stroke

    Time frame: 5 years

07

Study locations

64 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Aug 2027, 61 months after the start.

Of 79 non-industry observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 104. This study's planned 61 months is above that.

Counting every sponsor, half of 87 studies reached it within 50 months; a quarter within 30 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 19, 2022
StartActual
Jul 5, 2022
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05465122
Lead sponsor
Mayo Clinic
Responsible party
James F. Meschia (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jul 19, 2022
Start date
Jul 5, 2022
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
May 28, 2026

Study contacts

James Meschia, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion